|
Phase I Study of Anakinra to Treat Advanced Cancers that Produce Interluekin-1 Clinical Trials Info presented on Clinical Trials Search is not intended to be a substitute for certified medical advice, visits or professional assistance using a real physician. We are not physicians. Always consult your dr. about Phase I Study of Anakinra to Treat Advanced Cancers that Produce Interluekin-1 conditions. Clinical Trials Search.org is a site dedicated to listing clinical research studies in human subjects. Phase I Study of Anakinra to Treat Advanced Cancers that Produce Interluekin-1 Clinical research trials and Phase I Study of Anakinra to Treat Advanced Cancers that Produce Interluekin-1 health trials happen in many of localities throughout the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically measure the effectualness of new drugs. The function of the studies / projects is to resolve particular human medical questions. Clinical trials are a popular manner for mDs, government agencies, and private sector corporations to discover remedies for all varieties of circumstances, like Phase I Study of Anakinra to Treat Advanced Cancers that Produce Interluekin-1. Phase I Study of Anakinra to Treat Advanced Cancers that Produce Interluekin-1 Clinical Trials and other clinical trials allow volunteers to obtain healthcare treatment options before they are available to the masses. Some times the participants undergo professional assistance for free of charge, and occasionally they are paid for their time. Sometimes there is a cost for a Phase I Study of Anakinra to Treat Advanced Cancers that Produce Interluekin-1 clinical trial. Human subjects often get the best healthcare available for their Phase I Study of Anakinra to Treat Advanced Cancers that Produce Interluekin-1 condition. Dangers are a reality, however, and may include additional or frequent mD visits, healthcare dangers (potentially life-jeopardising), and/or the treatment being ineffectual. Trials are federally governed with rigorous guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "P" Clinical Trials Conditions > Phase I Study of Anakinra to Treat Advanced Cancers that Produce Interluekin-1  Phase I Study of Anakinra to Treat Advanced Cancers that Produce Interluekin-1
Phase I Study of Anakinra to Treat Advanced Cancers that Produce Interluekin-1
For Condition: Neoplasms
Status: Recruiting
Sponsor(s): National Cancer Institute (NCI) ,
Synopsis: This study will determine the maximum safe dose and side effects of the drug anakinra in patients with advanced cancer whose tumors produce a protein called interleukin-1. Approved by the Food and Drug Administration to treat rheumatoid arthritis, anakinra has shown potential for shrinking or slowing the progression of certain tumors that make interleukin-1. Patients 18 years of age and older with cancer that has spread from the primary site and whose tumor can be biopsied may be eligible for this study. Patients must have disease that has progressed after receiving standard chemotherapy or must have refused standard chemotherapy. Candidates will be screened with a medical history and physical examination, blood and urine tests, electrocardiogram, and imaging studies (x-rays, CT and MRI scans) to evaluate the location and extent of tumor. They will also have a tumor biopsy to determine if their tumor produces interleukin-1, a requirement for the study. For the biopsy, a small area of skin is numbed and a small piece of tumor is removed, either with a needle or by a small cut in the tumor. Participants will receive treatment with anakinra, given as a shot under the skin. Patients or a caregiver will be taught how to administer the injections. The dose of anakinra will be increased over time with different patients in a process called dose escalation in order to determine the most effective, yet safe, dose of the drug. Patients will be have blood tests weekly to determine blood levels of the drug, and a tumor biopsy and physical evaluation will be done every 2 months to evaluate response to therapy and side effects. Patients whose tumor remains stable or shrinks may be offered continued therapy for up to 6 months. Beyond that, continuation of therapy will be discussed between patient and physician. Patients whose tumor continues to grow while receiving anakinra will be taken off the study and alternative therapies will be discussed.
Details: In preclinical studies, we have demonstrated a potent anti-angiogenic effect of anakinra (recombinant interleukin-1 receptor antagonist (IL-1ra), Amgen INC., Thousand Oaks, CA) on human tumors xenografts or murine tumor allografts of various histologies that express either isoform of interleukin-1. Anakinra is FDA approved for the treatment of rheumatoid arthritis. In order to assess the potential anti-angiogenic effect of IL-1ra on human cancers, patients with interleukin-1 gene expression from tumor biopsies will receive subcutaneous injections of anakinra daily for two month long cycles using a phase I study design. Baseline tumor biopsies will be obtained from subjects while on protocol 99-C-0128, and TAQMAN RT-PCR will be used for analysis of interleukin-1 expression. Those patients found to have tumor biopsies expressing interleukin-1 will be eligible for this study. The endpoints of this study are to determine the dose-limiting toxicity (DLT), the maximum safe tolerated dose (MTD), pharmacokinetic profile of Anakinra (IL-1ra) administered in this setting, and any anti-tumor efficacy observed in treated patients. When feasible, tumor biopsies will be obtained after therapy to evaluate gene expression alterations that may occur due to inhibition of an angiogenic pathway.
Eligibility:
Study Type: Interventional, Treatment, Safety
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: INCLUSION CRITERIA: Patients with measurable metastatic cancer are eligible for evaluation. Patients must have disease that can be biopsied percutaneously with minimum morbidity on protocol 99-C-0128. Patients must have progressed while receiving standard first line chemotherapy or be unwilling to receive standard first line chemotherapy for their cancer. Patients must have had no chemotherapy, biologic therapy, or radiation therapy for their malignancy within 30 days prior to study entry. Patients may have received localized radiation therapy to non-target lesions provided that the radiotherapy is completed 14 days prior to commencing therapy, and the patient has recovered from any toxicity. Patients must have an ECOG performance status of less than or equal to 2. Patients must not have had any serious infection requiring antibiotic therapy for at least 30 days prior to inclusion on the study. Patients must be 18 years of age or older due to unknown effects of this drug in this drug in this pediatric population. Patients must have a platelet count greater than 75,000, an absolute neutrophil count greater than 1500/micro L, a PT within 2 seconds within the upper limit of normal, a total bilirubin of less than 1.5 mg/dL, and a serum creatinine less than or equal to 1.6 mg/ml unless the creatinine clearance greater than 30 mL/min/1.73 m(2). Patients must be willing to sign an informed consent, and undergo tumor biopsies to evaluate for alteration in IL-1 gene expression. Patients must have a tumor biopsy that constitutively expresses IL-1. EXCLUSION CRITERIA: Patients with non-measurable metastatic cancer or metastatic tumors which cannot be readily biopsied. Patients with active intracranial and leptomeningeal metastases will be excluded. Patients who have received resection or radiation therapy for intracranial metastatic disease may be eligible provided there is no evidence of active disease on MRI scan for greater than one month prior to commencing treatment and they require no anticonvulsant medication or steroids to control residual symptoms. Patients with life expectancy less than 4 months will be excluded. Patients who require systemic immune modulating medications including steroids will be excluded. Pregnant patients and lactating mothers will be excluded due to the unknown, potentially harmful effects of this agent on fetal and early childhood development. Patients with active infections will be excluded. Patients HIV will be excluded due to the potential risk of opportunistic infection.
Total Enrollment: 54
Location and Contact Information:
National Cancer Institute (NCI) *Recruiting*
Bethesda, Maryland, 20892
United States
Recruiting Patient and Public Liaison Office 1-800-411-1222
Additional Information:
Study ID Numbers: 030281; 03-C-0281
Study Start Date: August 26, 2003
Record last reviewed: August 21, 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00068016
Other Neoplasms Studies:
1. Phase I Study of Depsipeptide in Children with Cancer
2. Study of SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin in Advanced Malignancies: Continuous Infusion for 10 Days
3. Collection of Tissue Specimens from Patients with Solid Tumors or Blood Disorders and Their HLA-Compatible Family Members
4. Collection of Blood, Bone Marrow, Tumor or Tissue Samples
5. Endolymphatic Sac Tumors in a Population of Patients with von Hippel-Lindau Disease:The Natural History and Pathobiology, and a Prospective Non-Randomized Clinical Trial of Hearing Preservation Surgery in Patients with Early Stage Endolymphatic Sac Tumors
Related Studies:
Other Neoplasms Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
Phase I Study of Anakinra to Treat Advanced Cancers that Produce Interluekin-1
|
|
|
|
|
|
|
|
